DK2617431T3 - Polypeptidinhibitorer af HSP27-kinase og anvendelser derfor - Google Patents

Polypeptidinhibitorer af HSP27-kinase og anvendelser derfor Download PDF

Info

Publication number
DK2617431T3
DK2617431T3 DK13001411.1T DK13001411T DK2617431T3 DK 2617431 T3 DK2617431 T3 DK 2617431T3 DK 13001411 T DK13001411 T DK 13001411T DK 2617431 T3 DK2617431 T3 DK 2617431T3
Authority
DK
Denmark
Prior art keywords
kkka
polypeptides
disclosed
limited
methods
Prior art date
Application number
DK13001411.1T
Other languages
English (en)
Inventor
Brandon Seal
Brian Ward
Alyssa Panitch
Original Assignee
Purdue Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Purdue Research Foundation filed Critical Purdue Research Foundation
Application granted granted Critical
Publication of DK2617431T3 publication Critical patent/DK2617431T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/06Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/08Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Claims (4)

  1. PAT E NT K RAV
    1. Polypeptid bestående af sekvensen • WLRRIKAWLRRIKAWLRRIKAKALARQLGVAA; • RQRRKKRGKALARQLGVAA; • GRKKRRQRKALARQLGVAA; • YGRKKRRQRRRKALARQLGVAA; eller • WLRRIKAWLRRIKAKALARQLGVAA.
  2. 2. Biomedicinsk indretning omfattende polypeptidet ifølge krav 1, anbragt på eller i den biomedicinske indretning.
  3. 3. Biomedicinsk indretning ifølge krav 2, hvor den biomedicinske indretning er valgt blandt gruppen bestående af: en stent, et transplantat, en shunt, et stent-transplantat, en angioplastisk indretning, et ballonkateter, en fistel, en sårforbinding og en implanterbar lægemiddelafgivelsesindretning.
  4. 4. Sammensætning omfattende polypeptidet ifølge krav 1 og en farmaceutisk acceptabel bærer.
DK13001411.1T 2007-01-10 2007-07-16 Polypeptidinhibitorer af HSP27-kinase og anvendelser derfor DK2617431T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US88013707P 2007-01-10 2007-01-10
EP07836118.5A EP2155228B1 (en) 2007-01-10 2007-07-16 Polypeptide inhibitors of hsp27 kinase and uses therefor

Publications (1)

Publication Number Publication Date
DK2617431T3 true DK2617431T3 (da) 2017-07-10

Family

ID=39608928

Family Applications (3)

Application Number Title Priority Date Filing Date
DK13001412.9T DK2606903T3 (da) 2007-01-10 2007-07-16 Polypeptidinhibitorer af HSP27-kinase og anvendelser herfor
DK13001411.1T DK2617431T3 (da) 2007-01-10 2007-07-16 Polypeptidinhibitorer af HSP27-kinase og anvendelser derfor
DK07836118.5T DK2155228T3 (da) 2007-01-10 2007-07-16 Polypeptidinhibitorer af HSP27-kinase og anvendelser herfor

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK13001412.9T DK2606903T3 (da) 2007-01-10 2007-07-16 Polypeptidinhibitorer af HSP27-kinase og anvendelser herfor

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK07836118.5T DK2155228T3 (da) 2007-01-10 2007-07-16 Polypeptidinhibitorer af HSP27-kinase og anvendelser herfor

Country Status (7)

Country Link
US (3) US8536303B2 (da)
EP (3) EP2155228B1 (da)
AU (1) AU2007342674B2 (da)
CA (2) CA2689296C (da)
DK (3) DK2606903T3 (da)
ES (3) ES2594281T3 (da)
WO (1) WO2008085191A1 (da)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080293640A1 (en) * 2007-01-10 2008-11-27 Arizona Board of Regents, A body Corporate, of the State of Arizona, acting for and on behalf of Polypeptide inhibitors of HSP27 kinase and uses therefor
EP2155228B1 (en) 2007-01-10 2014-04-02 Purdue Research Foundation Polypeptide inhibitors of hsp27 kinase and uses therefor
EP2185698B1 (en) 2007-08-07 2015-04-22 Purdue Research Foundation Kinase inhibitors and uses thereof
EP3358354B1 (en) 2008-01-18 2020-07-15 President and Fellows of Harvard College Methods of detecting signatures of disease or conditions in bodily fluids
AU2009322865B2 (en) * 2008-10-20 2013-07-18 Moerae Matrix, Inc. Polypeptide for treating or preventing adhesions
ES2685505T3 (es) * 2008-12-10 2018-10-09 Purdue Research Foundation Inhibidor de cinasas basado en péptidos de permeación celular
AU2013202108B2 (en) * 2008-12-10 2015-12-24 Purdue Research Foundation Cell-permeant peptide-based inhibitor of kinases
WO2011017132A2 (en) * 2009-07-27 2011-02-10 Purdue Research, Foundation Mk2 inhibitor compositions and methods to enhance neurite outgrowth, neuroprotection, and nerve regeneration
WO2011149964A2 (en) * 2010-05-24 2011-12-01 Moerae Matrix, Inc., Methods for treating or preventing vascular graft failure
WO2012012694A2 (en) 2010-07-23 2012-01-26 President And Fellows Of Harvard College Methods of detecting autoimmune or immune-related diseases or conditions
EP2596353A4 (en) 2010-07-23 2014-01-15 Harvard College METHOD FOR DETECTING PRENATAL OR PREGNANT DISEASES OR SUFFERING
BR112013001752A2 (pt) 2010-07-23 2016-05-31 Harvard College método de detectar doenças ou condições usando células fagocídicas
BR112013001754A2 (pt) 2010-07-23 2016-05-31 Harvard College método para detectar marcas de doença ou condições em fluídos corpóreos
US9890200B2 (en) * 2011-04-12 2018-02-13 Moerae Matrix, Inc. Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition
BR112013026313A8 (pt) * 2011-04-12 2018-01-30 Moerae Matrix Inc composições e métodos para prevenir ou tratar doenças, condições ou processos caracterizados por proliferação anormal de fibroblastos e depósito de matriz extracelular
CA2747509C (en) 2011-05-12 2017-07-18 Oncogenex Technologies Inc. Treatment of pulmonary and pleural fibrosis using hsp27 inhibitors
WO2013134636A1 (en) 2012-03-09 2013-09-12 Purdue Research Foundation Compositions and methods for delivery of kinase inhibiting peptides
US20140072613A1 (en) * 2012-09-10 2014-03-13 Cynthia Lander Compositions and Methods for Treating Cutaneous Scarring
US10494675B2 (en) 2013-03-09 2019-12-03 Cell Mdx, Llc Methods of detecting cancer
US11585814B2 (en) 2013-03-09 2023-02-21 Immunis.Ai, Inc. Methods of detecting prostate cancer
US10336788B2 (en) * 2014-04-17 2019-07-02 Moerae Matrix, Inc. Inhibition of cardiac fibrosis in myocardial infarction
EP3693742B1 (en) 2014-09-11 2022-04-06 Harry Stylli Methods of detecting prostate cancer
WO2016081475A1 (en) * 2014-11-17 2016-05-26 Moerae Matrix, Inc. Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition
KR20170102900A (ko) 2015-01-08 2017-09-12 모레 매트릭스 인코포레이티드 Mk2 저해제 펩타이드의 제형
AU2016229017A1 (en) * 2015-03-12 2017-09-28 Moerae Matrix, Inc. Use of MK2 inhibitor peptide-containing compositions for treating non-small cell lung cancer with same
US10295527B2 (en) 2016-03-14 2019-05-21 Bruce Yacyshyn Process and system for predicting responders and non-responders to mesalamine treatment of ulcerative colitis
US11946927B2 (en) 2016-03-14 2024-04-02 Musidora Biotechnology Llc Process and system for identifying individuals having a high risk of inflammatory bowel disease and a method of treatment
JP7260087B2 (ja) * 2017-09-01 2023-04-18 エクセル メッド、エルエルシー ケロイドを治療するための医薬組成物及びその使用
CN115851946B (zh) * 2022-11-24 2023-09-01 中山大学孙逸仙纪念医院 CaMK I作为治疗靶点在制备胰腺癌治疗药物中的应用

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1521000A (en) * 1975-06-13 1978-08-09 Syntex Puerto Rico Inc Inhalation device
US4192309A (en) * 1978-09-05 1980-03-11 Syntex Puerto Rico, Inc. Inhalation device with capsule opener
US4227522A (en) * 1978-09-05 1980-10-14 Syntex Puerto Rico, Inc. Inhalation device
US4778054A (en) * 1982-10-08 1988-10-18 Glaxo Group Limited Pack for administering medicaments to patients
AU570013B2 (en) * 1982-10-08 1988-03-03 Glaxo Group Limited Medicament inhaler
CA1272917A (en) * 1985-07-30 1990-08-21 Paul Kenneth Rand Devices for administering medicaments to patients
US5175144A (en) * 1988-11-29 1992-12-29 The Johns Hopkins University Method of retarding the progression of chronic renal failure
JPH05963A (ja) 1990-04-13 1993-01-08 Toray Ind Inc ポリペプチド類組成物
AU654483B2 (en) * 1990-04-18 1994-11-10 University Of Utah Research Foundation Crosslinked hydrogels containing azobonds
CA2118513A1 (en) 1992-04-24 1993-11-11 David A. Zarling In vivo homologous sequence targeting in eukaryotic cells
US6582728B1 (en) * 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
ATE196311T1 (de) * 1993-12-09 2000-09-15 Univ Jefferson Verbindungen und verfahren zur ortsspezifischen mutation in eukaryotischen zellen
AU1818299A (en) 1997-12-10 1999-06-28 Washington University Anti-pathogen system and methods of use thereof
US7041814B1 (en) * 1998-02-18 2006-05-09 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to Enterobacter cloacae for diagnostics and therapeutics
US7601685B2 (en) * 1998-08-27 2009-10-13 Eidgenossische Technische Hochschule Zurich Growth factor modified protein matrices for tissue engineering
US7615373B2 (en) * 1999-02-25 2009-11-10 Virginia Commonwealth University Intellectual Property Foundation Electroprocessed collagen and tissue engineering
US20020009491A1 (en) * 2000-02-14 2002-01-24 Rothbard Jonathan B. Compositions and methods for enhancing drug delivery across biological membranes and tissues
ATE323517T1 (de) * 2000-08-15 2006-05-15 Surmodics Inc Matrix zur aufnahme von arzneimitteln
EP1351702B1 (en) * 2000-12-08 2015-03-04 Bioprovar Corporation Trem-1 splice variant for use in modifying immune responses
WO2002057413A2 (en) * 2001-01-18 2002-07-25 The Board Of Trustees Of The Leland Stanford Junior University Peptides for activation and inhibition of delta pkc
DE10118774A1 (de) * 2001-04-17 2002-10-31 Jerini Ag Verfahren zur Bestimmung der Substratspezifität einer enzymatischen Aktivität und Vorrichtung hierzu
US7361352B2 (en) * 2001-08-15 2008-04-22 Acambis, Inc. Influenza immunogen and vaccine
DK1523323T3 (da) * 2001-08-23 2013-10-28 Univ Arizona Reagenser og fremgangsmåder til behandlinger i den glatte muskulatur
US20030134810A1 (en) * 2001-10-09 2003-07-17 Chris Springate Methods and compositions comprising biocompatible materials useful for the administration of therapeutic agents
IL163575A0 (en) * 2002-02-21 2005-12-18 Univ Rockefeller Compositions and method for regulation of calcium-dependent signalling in brain
US20040005686A1 (en) * 2002-03-07 2004-01-08 Pharmacia Corporation Crystalline structure of human MAPKAP kinase-2
WO2003084481A2 (en) 2002-04-01 2003-10-16 Arizona Board Of Regents, A Body Corporate Acting On Behalf Of Arizona State University Biological affinity based delivery systems
CN1735687A (zh) 2002-08-02 2006-02-15 惠氏公司 Mk2相互作用蛋白
AU2003297431A1 (en) * 2002-12-20 2004-07-22 Pharmacia Corporation Mitogen activated protein kinase-activated protein kinase-2 inhibiting compounds
ES2268631T3 (es) 2003-02-21 2007-03-16 Arizona Board Of Regents Utilizacion de hsp20 para estimular la cicatrizacion de heridas y/o para reducir la formacion de cicatrices.
IL156429A0 (en) * 2003-06-12 2004-01-04 Peptor Ltd Cell permeable conjugates of peptides for inhibition of protein kinases
CA2542639A1 (en) 2003-10-17 2005-04-28 Arizona Board Of Regents Novel heat shock protein 20-related polypeptides and uses therefor
EP1766412B1 (en) * 2004-05-21 2009-04-01 The Institute for Systems Biology Compositions and methods for quantification of serum glycoproteins
US20060024264A1 (en) * 2004-07-23 2006-02-02 Kenichi Kuroda Antimicrobial copolymers and uses thereof
JP2008519861A (ja) * 2004-11-12 2008-06-12 マサチューセッツ・インスティテュート・オブ・テクノロジー 細胞増殖性疾患を治療するための方法および組成物
WO2006071456A2 (en) * 2004-12-02 2006-07-06 The University Of North Carolina At Chapel Hill Inhibition of hsp27 phosphorylation for treatment of blistering disorders
US7252729B2 (en) 2004-12-29 2007-08-07 Owens-Corning Fiberglas Technology Inc. Polymer/WUCS mat for use in sheet molding compounds
CA2603116A1 (en) * 2005-03-29 2006-10-05 The Regents Of The University Of California Controlling stem cell destiny with tunable network
EP1868629B1 (en) 2005-04-15 2014-10-22 Arizona Biomedical Research Commission Therapeutic fusion peptides for the treatment of metastatic cancer
AT502695A1 (de) 2005-10-20 2007-05-15 Voest Alpine Ind Anlagen Verfahren zur herstellung einer strangführungsrolle, eine nach dem verfahren hergestellte strangführungsrolle und deren verwendung
ES2628031T3 (es) * 2005-10-26 2017-08-01 Genesis Technologies Limited Matrices de regeneración tisular acelulares bioabsorbibles producidas mediante incubación de productos sanguíneos acelulares
CA2626868A1 (en) 2005-11-01 2007-05-10 The Arizona Board Of Regents, A Body Corporate Acting On Behalf Of Arizo Na State University Novel protein transduction domains and uses therefor
US20070154448A1 (en) * 2005-11-22 2007-07-05 Ted Reid Methods and compositions using Substance P to promote wound healing
BRPI0714383A2 (pt) 2006-07-12 2013-04-30 Univ Arizona mÉtodos para tratar e limitar desordens fibràticas e queloides
US20080293640A1 (en) * 2007-01-10 2008-11-27 Arizona Board of Regents, A body Corporate, of the State of Arizona, acting for and on behalf of Polypeptide inhibitors of HSP27 kinase and uses therefor
EP2155228B1 (en) * 2007-01-10 2014-04-02 Purdue Research Foundation Polypeptide inhibitors of hsp27 kinase and uses therefor
EP2185698B1 (en) * 2007-08-07 2015-04-22 Purdue Research Foundation Kinase inhibitors and uses thereof
WO2009123759A2 (en) 2008-04-02 2009-10-08 Moerae Matrix, Inc. Therapeutic uses of biocompatible biogel compositions
AU2009322865B2 (en) * 2008-10-20 2013-07-18 Moerae Matrix, Inc. Polypeptide for treating or preventing adhesions
ES2685505T3 (es) 2008-12-10 2018-10-09 Purdue Research Foundation Inhibidor de cinasas basado en péptidos de permeación celular
WO2011017132A2 (en) 2009-07-27 2011-02-10 Purdue Research, Foundation Mk2 inhibitor compositions and methods to enhance neurite outgrowth, neuroprotection, and nerve regeneration
WO2011149964A2 (en) * 2010-05-24 2011-12-01 Moerae Matrix, Inc., Methods for treating or preventing vascular graft failure
BR112013026313A8 (pt) 2011-04-12 2018-01-30 Moerae Matrix Inc composições e métodos para prevenir ou tratar doenças, condições ou processos caracterizados por proliferação anormal de fibroblastos e depósito de matriz extracelular

Also Published As

Publication number Publication date
EP2617431A2 (en) 2013-07-24
EP2617431B1 (en) 2017-04-12
US20140112947A1 (en) 2014-04-24
EP2617431A3 (en) 2013-12-11
EP2155228A1 (en) 2010-02-24
CA2898230A1 (en) 2008-07-17
CA2898230C (en) 2018-04-24
CA2689296C (en) 2015-11-17
DK2155228T3 (da) 2014-07-07
ES2624196T3 (es) 2017-07-13
US8536303B2 (en) 2013-09-17
ES2476842T3 (es) 2014-07-15
DK2606903T3 (da) 2016-12-05
ES2594281T3 (es) 2016-12-19
US20090196927A1 (en) 2009-08-06
US9649354B2 (en) 2017-05-16
EP2606903A1 (en) 2013-06-26
WO2008085191A1 (en) 2008-07-17
EP2155228A4 (en) 2010-06-16
AU2007342674A1 (en) 2008-07-17
CA2689296A1 (en) 2008-07-17
US20170072009A1 (en) 2017-03-16
EP2606903B1 (en) 2016-09-14
EP2155228B1 (en) 2014-04-02
US9493508B2 (en) 2016-11-15
AU2007342674B2 (en) 2013-09-19

Similar Documents

Publication Publication Date Title
DK2617431T3 (da) Polypeptidinhibitorer af HSP27-kinase og anvendelser derfor
US20080293640A1 (en) Polypeptide inhibitors of HSP27 kinase and uses therefor
JP5552470B2 (ja) 平滑筋治療用薬剤および方法
AU2007272578B2 (en) Methods for treating and limiting fibrotic disorders and keloids
AU2004281838B2 (en) Novel heat shock protein 20-related polypeptides and uses therefor
AU2013273708B2 (en) Polypeptide inhibitors of HSP27 kinase and uses therefor
US11149064B2 (en) Vasoactive polypeptides for smooth muscle relaxation